攝護腺特異抗原是一個具有高敏度的血清腫瘤標記，所以常被用來追蹤攝護腺癌病人治療後的結果。攝護腺癌的生長受雄性激素的影響很大，所以目前雄性激素阻斷常被用來治療第D期攝護腺癌病人，從1990年4月到1995年4月，共有74位第D期攝護腺癌病人接受睪丸切除術，其中24人規則地每隔2~3個月在門診接受血清中攝護腺特異抗原檢查。其中12位只接受血清中攝護腺特異抗原檢查。其中12位只接受去勢手術的病人我們歸類在第一組，另外12位去勢手術後又接受抗雄性激素藥物治療的病人歸類在第二組。結果發現第一組病人血清中攝護腺特異抗原值平均在術後7.3個月降到最低點，而在10.6個月後再度升高；在第二組病人血清中攝護腺特異抗原值平均在術後9.9個月降到最低點，而在7.8個月後再度升高。這些數值並沒有統計學上的意義。因此，從有限的初步經驗中，我們希望提供了對第D期攝護腺癌的病人接受睪丸切除術後，是否須再接受完全雄性激素阻斷治療的另外一種思維。

Prostate-specific antigen (PSA) is a unique serum marker highly sensitive to any form of therapy for prostatic cancer. Based on the character of hormonal dependence of the cancer cell, and rogen ablation is one of the best therapies for advanced prostatic cancer. From April 1990 to April 1995, 74 patients with the diagnosis of stage D prostatic cancer had received bilateral orchiectomy. Twenty-four of them had completed regular follow-up at our out-patient clinic. Serum PSA level was checked every two to three months and analyzed. Twelve patients who had no adjuvant anti-androgen therapy were categorized as group I. Another twelve patients who received post-operative anti-androgen medication were categorized as group II. In the group I patients, the serum PSA level reduced to the minimum 7.3±5.2 months after orchiectomy but relapsed 10.6±10.6 months later. In the group II patients, the post-operative PSA level reduced to the minimum in 9.9±6.6 months and raised 7.8±5.7 months later. There were no statistic differences between both groups (p>0.05, Student’s t test). Our preliminary results, warranted no conclusion on the role of adjuvant complete androgen blockade therapy for stageD prostatic adenocarcinoma.